IMU

5.56%

5.7¢ imugene limited

You can look at CSL and their failure with clinical trials....

First 21865 Last

Share
Profile

Follow
B2ON5ON

65 Posts.

9

10/03/24

15:05

Post #: 72832147
Share

Originally posted by Ragnarolf: ↑

Hi Ben,
You seem to be talking around the elephant in the room, if not have a confused position on what defines success for Imugene.
There is no denying that Hervaxx was good science; It produced statistically significant data that showed an overall reduction in harm and a survival benefit to the participating patients.
Though cutting through the radio silence from Leslie. Hervaxx will never get out of phase 2 as its simply too difficult to recruit eligible patients to produce sufficient data to get Hervaxx into a registrational trial. (The patients who were eligible for the Next Horizon trial are often sadly too unwell to participate and be enrolled). Therefore the commercial decision was made to deprioritise Hervaxx and invest the time, money, and resources into more promising technology platforms the company owns.
At its core Imugene is a trading company on the ASX raising funds from shareholders to deliver a commercial return. It is not an incorporated non-for-profit charitable organisation rising funds via donations to pursue cancer research. (Home Research Lottery and many others if that is what one is seeking)
I would disagree to say there is no transferable research for Hervaxx’s “proof of concept” that adds any commercial value to out other technology platforms. So unless Hervaxx can be on sold to another suitor it will add no benefit to the company after the decade of time, effort, and money spent progressing the science.
To any fellow shareholder and investors, Hervaxx should act as cautionary tail that there are no guarantees in Biotech’s. And that even if your product works, that in itself is not sufficient to guarantee success and a commercial outcome.
DYOR / IMO / Not financial advice

Expand

You can look at CSL and their failure with clinical trials. Nothing is guaranteed, whether you're market cap is 800M or 800B.

IMU Price at posting: 11.0¢ Sentiment: Hold Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

RCE

Recce's R327 found effective against E.coli during clinical trial

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

There are more pages in this discussion • 3,195 more messages in this thread...

First 21865 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.7¢		Change 0.003(5.56%)		Mkt cap ! $417.2M

Open	High	Low	Value	Volume
5.5¢	5.8¢	5.2¢	$2.499M	45.00M

Buyers (Bids)

No.	Vol.	Price($)
2	1921794	5.6¢

Sellers (Offers)

Price($)	Vol.	No.
5.7¢	1368288	7

View Market Depth

No.	Vol.	Price($)
5	286362	0.055
9	2036888	0.054
16	2736044	0.053
20	1943436	0.052
23	3206056	0.051

Price($)	Vol.	No.
0.057	378902	2
0.058	1552127	7
0.059	837099	8
0.060	2176188	16
0.061	1163926	6

Last trade - 16.10pm 28/06/2024 (20 minute delay)

IMU (ASX) Chart

You can look at CSL and their failure with clinical trials....

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

You can look at CSL and their failure with clinical trials....

Top Stories

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News